Skip to main content

Table 2 Difference in frailty and immune cell profiles pre-, post-, and 6 months post-chemotherapy

From: The longitudinal relationship between immune cell profiles and frailty in patients with breast cancer receiving chemotherapy

  Pre-chemo N (%) Post-chemo N (%) 6 months post-chemo N (%) Pre- vs post-chemo (p value) Pre- vs 6 months post-chemo (p value)
Frailty components
 Weakness ≥ 4 145 (25.0) 290 (54.3) 153 (30.2) < 0.001 0.056
 Exhaustion ≥ 4 230 (39.7) 342 (63.9) 214 (42.3) 0.008 0.378
 Walk speed < 2 mph 313 (54.5) 353 (66.6) 254 (50.7) < 0.001 0.210
 Physical activity < 150 min/week 53 (9.2) 76 (14.3) 30 (6.0) 0.008 0.049
Frailty score: N (%)
 0 173 (29.8) 74 (13.8) 154 (30.4) < 0.001 0.480
 1 195 (33.6) 122 (22.8) 151 (29.8)
 2 109 (18.8) 124 (23.1) 115 (22.7)
 3 88 (15.2) 173 (32.3) 74 (14.6)
 4 16 (2.8) 43 (8.0) 12 (2.37)
 Mean [SD] 1.3 [1.1] 2.0 [1.2] 1.3 [1.1] < 0.001 0.846
Cell counts: mean [SD]
 Neutrophils (103 cells/μL) 4.69 [2.68] 4.84 [5.01] 0.560
 Lymphocytes (103 cells/μL) 1.88 [0.97] 1.22 [1.48] < 0.0001
 Monocytes (103 cells/μL) 0.53 [0.55] 0.54 [0.53] 0.947
 NLR 3.00 [2.98] 5.03 [5.71] < 0.001
 LMR 5.72 [31.2] 2.8 [1.98] 0.038
 Total WBC (103 cells/μL) 7.42 [3.05] 6.59 [4.76] < 0.001
 Hemoglobin (g/dL) 12.67 [2.28] 11.12 [1.58] < 0.001
 Hematocrit (%) 37.50 [6.92] 33.26 [4.65] < 0.001
 Platelets (103 cells/μL) 260.27 [81.82] 237.93 [89.16] < 0.001
 Albumin (g/dL) 4.17 [0.43] 3.93 [0.47] < 0.001
  1. SD standard deviation, μL microliter, g gram, dL deciliter, % percent, NLR neutrophil to lymphocyte ratio, LMR lymphocyte to monocyte ratio, WBC white blood cell